Ayuna

Quick links to important sections

Ayuna

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ayuna

Quick Facts

Property Description
Active ingredient Ethinyl Estradiol and Levonorgestrel
Form Oral tablet (cyclical pack)
Pharmacological class Combination hormonal contraceptive (COC)
Common use Prevention of pregnancy
Origin Synthetic

What Type of Medicine is Ayuna?

Ayuna is a prescription-only pharmaceutical product classified as a combination hormonal contraceptive (COC), specifically indicated for use by females of reproductive potential to prevent pregnancy. The drug is consistently administered via the oral route in a structured tablet dosage form. This identity is supported by pharmacological studies that confirm the efficacy of dual-hormone formulations in providing robust birth control. The medication is widely recognized in clinical practice as a standard option for systemic contraception.

Composition and Origin: Ethinyl Estradiol and Levonorgestrel

Ayuna is defined as a synthetic combination product containing the active ingredients Ethinyl Estradiol, which functions as the synthetic estrogenic compound, and Levonorgestrel, which serves as the synthetic progestogen. The quality standards for these pharmaceutical substances are established and confirmed by regulatory authorities like the United States Pharmacopeia (USP). The product's form is also distinctive, packaged as a 28-day cycle of tablets that includes both hormone-containing active tablets and a set of non-hormonal inert tablets.

General Principle of Action

The fundamental purpose of Ayuna is the highly reliable prevention of pregnancy, a goal achieved through a strategic multi-target mechanism of effect that provides comprehensive contraceptive control. This efficacy is maintained by the synergistic action of the combined hormones. The benefit of using this medication is the achievement of systemic, non-barrier based contraception, a factor clinically recognized for its high effectiveness when compliance is ensured. This provides a reliable method of preventing pregnancy for women managing their reproductive health.

Regulatory References

  1. Birth control pills - combination: MedlinePlus Medical Encyclopedia
  2. LEVONORGESTREL AND ETHINYL ESTRADIOL kit - DailyMed

What side effects are possible with Ayuna?

Possible Side Effects and Safety Information

The safety profile of Ayuna, as documented in regulatory sources, necessitates awareness of both common adverse reactions and the potential for serious, rare events.

Serious and Clinically Significant Risks

Ayuna carries a Boxed Warning regarding the increased risk of serious cardiovascular events, including thromboembolic disorders (such as deep vein thrombosis and pulmonary embolism), myocardial infarction (heart attack), and stroke. This risk is significantly heightened in women over 35 years of age who smoke. Other serious, but less common, adverse reactions documented include liver tumors (hepatic adenomas and carcinoma), gallbladder disease, and the development or worsening of hypertension (high blood pressure).

Common Adverse Reactions

The most frequently reported adverse reactions, occurring in 1% or more of users, are primarily related to the reproductive and gastrointestinal systems. These include nausea and vomiting (up to 11%), abdominal pain/cramps, breast tenderness or enlargement, intermenstrual bleeding (spotting), and acne. Breakthrough bleeding or spotting is especially common during the initial three months of use.

Population-Specific Restrictions

Ayuna is contraindicated in patients with a history of or current venous or arterial thrombotic diseases, severe or uncontrolled hypertension, migraine with aura, liver disease (including tumors or acute hepatitis), and known or suspected hormone-sensitive cancers (such as breast cancer). Use is also restricted in women over 35 who smoke, and it is contraindicated during pregnancy.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for combination hormonal contraceptives (COCs), such as Ayuna (Ethinyl Estradiol and Levonorgestrel), characterizes acute overdosage as having low acute toxicity and being unlikely to be life-threatening. While severe outcomes are uncommon, specific clinical manifestations are documented.

Documented Overdose Manifestations

Property Official Regulatory Statement
Common Presentation Nausea, vomiting, and subsequent withdrawal bleeding (vaginal bleeding). Other reported signs may include breast tenderness and headache.
Population-Specific Note Vaginal bleeding may occur in prepubertal females who have ingested the product due to exposure to the estrogen component.

Emergency Action and Management

In the event that an overdose is suspected, an individual should call a Poison Control Center right away for specific guidance or seek medical help immediately for an evaluation. Urgent medical assistance is required if the person exhibits serious or rapidly escalating symptoms, such as passing out or having trouble breathing. Regulatory sources confirm that no specific antidote is known for the active components. Consequently, management in a clinical setting is focused on providing symptomatic and supportive treatment. This often includes monitoring the patient’s vital signs as part of standard observation requirements.

Therapeutic Uses of Ayuna

What Ayuna Treats: Main Uses and Benefits

The therapeutic application of Ayuna (Ethinyl Estradiol and Levonorgestrel) is centered on pregnancy risk management and the management of several symptomatic, hormone-dependent conditions in females of reproductive potential. This class of medication is commonly applied to address secondary therapeutic needs such as heavy or irregular menstruation and acne.


Therapeutic Domains and Symptom Support

The medication's primary function is supporting systemic contraception, which assists with maintaining functional stability for individuals involved in routine reproductive planning. Beyond this primary use, Ayuna is commonly used across conditions characterized by periods of heightened symptoms related to the menstrual cycle and hormonal balance.

It helps manage symptom clusters involving severe menstrual cramps (dysmenorrhea), heavy menstrual bleeding (HMB), persistent acne vulgaris, and the significant symptoms of Premenstrual Dysphoric Disorder (PMDD). Ayuna is applied in settings where additional symptomatic support is needed. This provides supportive relief that contributes to improved comfort during symptomatic periods.

Quick Fact: Relief for Symptomatic Menstruation
Commonly used to help with Heavy menstrual bleeding (HMB) and severe menstrual cramps (dysmenorrhea)
Supportive benefit Helps establish predictable, lighter, and generally more regular cycles

Regulatory References

  1. NIH MedlinePlus overview on Ethinyl Estradiol and Levonorgestrel

Eligibility and Restrictions for Use

Ayuna is officially indicated for use by females of reproductive potential who have reached menarche. Regulatory documents outline strict eligibility and non-eligibility criteria, classifying certain groups as absolutely contraindicated due to heightened risk.

Eligibility Status Populations Excluded or Restricted
Contraindicated Females over 35 who smoke; those with a history of thromboembolic events (DVT, PE, stroke) or thrombogenic disorders (e.g., hypercoagulopathies).
Females with a history of breast cancer, liver tumors, severe cirrhosis, or migraines with aura.
Females with uncontrolled hypertension or diabetes mellitus with vascular disease.
Not Recommended Pregnant females (contraindicated status). Lactating women (due to the potential for decreased milk production).
Age Limitations Not indicated before menarche or after menopause.

Use is subject to specific restrictions, including temporary discontinuation 4 weeks before and through 2 weeks after major surgery or during periods of prolonged immobilization. Postpartum initiation must start no earlier than 4 weeks after delivery for non-breastfeeding females. The official eligibility profile is defined by the absence of major cardiovascular, hepatic, and malignancy risks, as documented by regulatory authorities.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Ayuna (levonorgestrel/ethinyl estradiol) is a combination hormonal contraceptive whose efficacy and safety can be affected by co-administration with other medications. The most severe interaction is a contraindication with certain Hepatitis C virus (HCV) drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to a significant risk of ALT (liver enzyme) elevations. These hormonal products must be discontinued prior to starting the HCV regimen.

Other clinically significant interactions primarily stem from effects on the metabolism of the active ingredients. Drugs that induce CYP3A4 enzymes (e.g., certain anticonvulsants, antifungals, or St. John’s wort) can decrease the systemic exposure of ethinyl estradiol and may lead to a reduction in contraceptive efficacy or increased breakthrough bleeding. Conversely, strong CYP3A4 inhibitors may increase the plasma concentration of both hormonal components.

Specific administration constraints apply to colesevelam, a bile acid sequestrant. Because it significantly decreases ethinyl estradiol exposure, Ayuna must be administered at least 4 hours before colesevelam to minimize this effect. Additionally, co-administration with lamotrigine can significantly reduce the lamotrigine level due to the contraceptive's inductive effect on glucuronidation, which can compromise seizure control.

Mechanism of Action

Ayuna is a pharmacological agent that operates by precise molecular engagement, leading to a cascade of effects that modify specific biological processes. Its mechanism of action is primarily concentrated in two key domains.


Activity at Specific Receptor Subtypes

This domain covers Ayuna's activity at distinct receptor subtypes responsible for transmitting signals within the target signaling pathway. By acting as an agonist or antagonist at these targets, the drug modifies the initial molecular steps, resulting in attenuation of pathway signaling and maintenance of a modified basal activity level within the target pathways.


Engagement with Target Enzyme Pathways

Ayuna engages mechanisms that target specific enzymes involved in the synthesis or breakdown of key signaling mediators. This modulation influences the concentration and duration of action of these mediators, thereby altering the magnitude of downstream signaling. This results in reduced levels of active signaling mediator, culminating in an altered systemic physiological state.

Dosage and Administration Information

Instruction Map: How to use Ayuna — Official Administration Guidelines

Ayuna is a combination hormonal product governed by specific, structured usage protocols. Its administration is centered on maintaining a fixed, 24-hour dosing interval throughout a repeating cycle.


Administration Scope

Feature Administration Instructions
Route of administration Oral (tablet must be swallowed whole).
Dosing schedule One active tablet taken once daily at the same time each day.
Timing in relation to meals May be taken with or without food.
Age-group administration rules Indicated for postmenarchal females; use is not indicated for postmenopausal women.
Missed-dose rules Specific protocols exist for managing one or more missed active tablets, which often require the temporary use of backup nonhormonal contraception.

Instruction Classifications (High-Level)

Classification Description
Administration method type Oral (swallowed tablet)
Frequency pattern Daily (once every 24 hours); Cyclic (28-day or 91-day repeating sequences).
Use-context constraints Requires strict adherence to the fixed 24-hour interval and defined initiation procedures.

Resulting Procedural Structure

Official step sequence:

  • One tablet is taken orally once daily following either a 28-day or 91-day regimen structure.
  • The dosing pattern involves consecutive daily use of active tablets, followed by a scheduled 7-day interval of inert (placebo) tablets or low-dose estrogen.
  • Regimen initiation follows prescribed protocols, such as the Day 1 Start or Sunday Start, which defines when the first tablet of the first cycle is taken.

Connection to the overall use protocol (2–4 sentences):

These official instructions establish a continuous, cyclical use protocol requiring strict adherence to a fixed daily time to ensure the standardized administration of the product. The protocol defines the precise sequence for transitioning between the hormone-containing and non-hormonal phases of the cycle. Specific procedural steps are provided for managing deviations, such as missed-dose contingency rules, to restore the established usage pattern.

Recent Clinical Evidence

Research evidence / Overview of studies for Ayuna

Evidence for Preventing Pregnancy (Contraception)

The research into this medicine was studied for systemic contraception, with an evidence base derived from large, short-term Randomized Controlled Trials (RCTs) and long-term observational studies. Researchers focused on quantifying the rate of unintended pregnancy, which is monitored using the Pearl Index (pregnancies per 100 woman-years of use).

Studies reported measurements of the Pearl Index, describing the patterns observed in the cohorts evaluated. Research provides context about the measured patterns of cycle changes in the cohorts evaluated, but not individual predictions.

Evidence for Managing Heavy Menstrual Bleeding (HMB) and Severe Menstrual Cramps

This medicine was evaluated in research exploring how symptoms change over time in conditions characterized by fluctuating or episodic manifestations, such as heavy menstrual bleeding and dysmenorrhea. Studies included RCTs that compared the medicine to a placebo or other standard therapies, and these findings were later included in broader Systematic Reviews.

Studies monitored outcomes related to physical discomfort and the volume of menstrual blood loss (MBL), often using validated pain scales and objective MBL measurements. Research describes reported measurements of pain severity and menstrual blood loss (MBL) across the study period.

Evidence for Treating Moderate Acne Vulgaris

Research includes evidence from Randomized, double-blind, placebo-controlled clinical trials that examined this medicine for outcomes related to inflammatory or irritative states, specifically for the treatment of moderate acne vulgaris.

Studies monitored changes in both inflammatory and non-inflammatory acne lesion counts. Researchers also assessed the overall appearance of the skin by means of the Clinician Global Assessment (CGA) score. Research describes the short-term changes measured, and studies reported how outcomes were measured in the observed populations over approximately six menstrual cycles.

Research Gaps and Remaining Uncertainties

The evidence base for this medicine shows several limitations. The full range of comparative evidence is not yet complete. Follow-up durations were limited in many primary trials, meaning the long-term effects are not fully established. Research exploring outcomes in women with high Body Mass Index (BMI) appears to be limited, and the findings on contraceptive effectiveness in this group are not yet comprehensive. Research does not determine whether an individual will respond similarly, as study results reflect the specific conditions under which they were conducted.

Key Studies & References Contraceptive considerations in obese women (guideline/review referencing BMI and contraceptive efficacy)

Frequently Asked Questions (FAQ)

Common questions about Ayuna (FAQ)

Q: What key facts about Ayuna are highlighted by major regulatory agencies like the FDA?

Major regulatory agencies like the FDA highly emphasize the Boxed Warning for this medication. This warning concerns the increased risk of serious cardiovascular events, including blood clots, stroke, and heart attack. This risk is noted in regulatory information to be significantly heightened for women over 35 who smoke.

Q: What is the patient information leaflet required to communicate about Ayuna?

The Patient Information Leaflet (PIL) or Medication Guide is required to communicate critical safety information to the user. This includes the details of the Boxed Warning, essential instructions on how to take the pills, information regarding the management of a missed dose, and a comprehensive list of warnings and possible side effects.

Q: Is there a generic alternative for the drug Ayuna available?

Yes, Ayuna is a specific brand name for the generic drug combination levonorgestrel and ethinyl estradiol. Official drug information confirms that this combination is widely available and marketed under multiple generic and other brand names.

Q: Are there different dosage strengths of Ayuna available?

The active ingredients, levonorgestrel and ethinyl estradiol, are available in various formulations. Official drug information lists multiple monophasic, biphasic, triphasic, and extended-cycle options containing different dose combinations.

Q: What is the typical expected length of time for a course of Ayuna treatment?

The medication is designed for a continuous, cyclical use protocol. Regulatory protocol describes that use is intended to be continued in repeating cycles (such as 28-day or 91-day) for as long as the contraceptive method is desired and the medication is well-tolerated.

Q: When do most patients typically begin to notice the full effect of Ayuna?

For contraceptive purposes, official instructions mention that a backup method is advised for the first seven days. Efficacy information suggests that the contraceptive effect begins after seven consecutive active pills are taken. For other approved indications, the time required to notice the full clinical effect may vary.

Q: Is it normal to not see immediate improvement after starting Ayuna?

Yes, it is considered normal not to see immediate improvement, especially since official instructions advise that full contraceptive protection typically begins after seven days of consecutive active pills. Additionally, certain common side effects, such as spotting, are often noted during the initial months of use.

Q: How can a patient generally know if Ayuna is having the intended effect?

For contraception, the primary goal of the medication is preventing pregnancy. For secondary uses approved in clinical trials, such as treating heavy menstrual bleeding or acne, effectiveness is assessed by observed changes in symptoms or lesion counts over time.

Q: How long does the drug Ayuna stay in the body after the last dose?

The active ingredients have defined elimination times based on pharmacokinetic data. Official sources indicate that the terminal elimination half-life for levonorgestrel is approximately 34 hours, and for ethinyl estradiol, it is about 18 hours.

Q: Are there specific steps for discontinuing use of Ayuna as described in official documents?

Yes, official documents describe specific conditions under which the medication must be temporarily or permanently stopped. These situations include stopping at least four weeks before a major surgery, or immediately if serious conditions like a thrombotic event or jaundice occur.

Q: Is it normal to have certain minor symptoms right after starting a new medication like Ayuna?

Yes, regulatory information notes that common, minor side effects may occur, particularly during the first few months of use. These symptoms can include nausea, headache, breast tenderness, and spotting (vaginal bleeding between periods).

Q: How long do initial side effects usually last after starting Ayuna?

Many common initial side effects tend to be temporary. Regulatory information notes that irregular bleeding or spotting is often reported to resolve within the first three months of use. In general, common side effects may be expected to improve or resolve within the first few treatment cycles.

Q: What general precautions should be followed to reduce common side effects of Ayuna?

For common issues like nausea or stomach upset, official patient information suggests methods for management. Taking the medication after an evening meal or at bedtime may be considered to potentially lessen these symptoms.

Q: Does the risk of side effects increase with long-term use of Ayuna?

The risk of serious side effects is primarily linked to underlying patient risk factors, such as smoking and age (over 35). Regulatory documents confirm that appropriate monitoring is recommended for patients who use the medication long-term.

Q: Is fatigue a common experience when taking Ayuna?

Official regulatory sources list a lack of energy or fatigue as a possible side effect. This is one of the various adverse reactions noted in the product information.

Q: Can Ayuna affect sleep patterns or cause insomnia?

Difficulty in sleeping or sleeplessness (insomnia) is listed in official sources as a possible side effect of the medication.

Q: Does Ayuna affect mental clarity or memory function?

Official warnings note that the medication may cause mental or mood changes. This includes the development or worsening of depression or other emotional disorders.

Q: Is it true that Ayuna can cause changes in routine lab test results?

Yes, the hormonal components may affect the results of certain routine lab tests. Regulatory warnings state that the estrogen component may raise the concentrations of specific binding globulins and may also affect glucose tolerance or lipid levels.

Q: Are there any known interactions between Ayuna and common prescription medicines?

Official label documents list several clinically significant interactions. These include specific contraindications with certain Hepatitis C virus drugs, and interactions with CYP3A4 enzyme-inducing drugs (like some anticonvulsants) and certain medicines used for seizure control.

Q: Do vitamins or herbal supplements typically interact with Ayuna?

The efficacy of the medication is affected by substances, including certain herbal products and supplements, that influence liver enzymes (specifically CYP3A4). These substances can either reduce or increase the concentration of the hormones in the body, which requires awareness of the potential for interactions.

Q: Does Ayuna interact with everyday foods or drinks?

Regulatory information notes that certain non-drug substances can interact with the medication. Specifically, grapefruit or grapefruit juice may potentially increase the drug's concentration in the blood, and an interaction with caffeine has also been noted.

Q: Does grapefruit juice affect how the body processes Ayuna?

Yes, official regulatory information confirms that grapefruit juice can potentially affect the metabolism of the estrogen component. This may lead to an increase in the estrogen's concentration in the body, which could potentially increase the risk of associated side effects.

Q: Is there a known interaction between Ayuna and caffeine products?

Yes, official interaction information notes that the estrogen component may affect the way the body processes caffeine. This can lead to increased blood levels of caffeine, which could potentially worsen caffeine-related side effects such as nervousness or sleeplessness.

How should Ayuna be stored and disposed of?

The official labeling dictates strict conditions for the storage and disposal of Ayuna (levonorgestrel/ethinyl estradiol) tablets to maintain product efficacy and stability.

Required Storage Conditions
Temperature: Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F). Do not freeze or refrigerate.
Protection: Keep in the original, tightly closed container or blister packaging to protect from light and moisture.
Safety: Must be kept out of the sight and reach of children.

Unused or expired medication must be disposed of properly. The recommended procedure is to return the product to a drug take-back program or follow the official household disposal guidance (e.g., mixing with an undesirable substance) instead of flushing it down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ayuna found in:

A-Z Index: